MedTrace Logo

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

NCT03851263 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-12-06

No results posted yet for this study

Summary

The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis.

Conditions

Interventions

BIOLOGICAL

Evolocumab

Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • GE Healthcare

    collaborator INDUSTRY

  • HeartFlow, Inc.

    collaborator INDUSTRY

  • ECRI bv

    lead INDUSTRY

Principal Investigators

  • Patrick W Serruys, Prof. dr. · NHLI Imperial College, London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-30
Primary Completion
2021-08-27
Completion
2023-02-24

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03851263 on ClinicalTrials.gov